News

Progressive MS trial of vidofludimus calciumĀ fully enrolled

A global Phase 2 clinical trial investigating theĀ oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calciumĀ seen in…

EMBOLD data covering over 90 MS patients now due in November

Atara Biotherapeutics now is planning to announce in November the one-year data from its EMBOLD Phase 1/2 study, which is testing the company’s experimental treatment ATA188 for progressive forms of multiple sclerosis (MS). The results, originally expected in October, will cover the trial’s primary endpoint of…

Pilates with relaxation improves walking, self-awareness in MS

Pilates exercise with a relaxation technique improved walking abilities and self-awareness among people with multiple sclerosis (MS), according to a small study. The study, “Impact of Pilates suspension with self-awareness on gait and metacognition in multiple sclerosis: Randomized, single-blinded and parallel-group trial,” was published in…

Walking loss more rapid among marginalized MS patients in US

People with multiple sclerosis (MS) with a rapid decline in walking abilities were more likely to be older when first examined, female, or Black, according to a large data study in the U.S. Other factors associated with worsening walking impairment over time included living with MS longer, having progressive…

Neuro Night event to raise funds for neurological care, research

Neuro Night, a philanthropic event set for October in Scottsdale, Arizona, is raising funds for the Barrow Neurological Institute and its mission of supporting the lifesaving care, medical education, and research for neurological diseases. The star-studded night of music, dancing, and fundraising, hosted by the Barrow Neurological Foundation,…

Physical activity may reduce fatigue in people with RRMS: Trial

More daily physical activity, better physical condition, and lower disability were all associated with less fatigue for people with relapsing-remitting multiple sclerosis (RRMS), according to a clinical trial in Finland. ā€œThe findings are interesting and support previous studies very well,” Marko Luostarinen, a doctoral researcher at the University of…

Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3

Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…

US neurologists satisfied with current RRMS therapies: Report

Neurologists in the U.S. are largely satisfied with current treatment options for relapsing-remitting multiple sclerosis (RRMS), but opportunities remain for therapies in development, according to a new report by Spherix Global Insights. In the report series, called RealTime Dynamix: Multiple Sclerosis (U.S.), an ongoing survey of healthcare…

NfL blood test may detect neurodegeneration in youngsters

Neurofilament light chain (NfL) protein levels can be used to assess neurodegeneration in children and adolescents with neurological disease, including multiple sclerosis (MS), even when they are not experiencing any symptoms, a study has found. The protein already had been established as a biomarker of disease activity and poor…

Benefits of ketogenic diet in RRMS may be long lasting: Study

Following a ketogenic diet ā€” one that’s low in carbohydrates and rich in fat ā€” for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study showed.